Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Avita Medical, Inc. Common Stock

RCEL

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Last trade $15.64
Day change +$0.42 (+2.76%)
Day range $15.16 – $16.30
Volume 276,276
Market cap $482M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$482.29M
Price / earnings
—
Price / book
-15.54×
Price / sales
5.7×
EV / sales
6.11×
EV / EBITDA
-19.76×

Profitability

Earnings per share
-$1.14
Return on assets
-77.18%
Return on equity
116.37%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.47×
Current ratio
1.2×
Quick ratio
0.99×
Cash ratio
0.46×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RCEL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$26.11M$21.7M$19.25M$17.62M$17.06M$18.42M$18.51M$18.41M
Cost of revenue$4.17M$3.94M$3.52M$3.3M$3.19M$3.47M$2.83M$2.28M
Gross profit$21.94M$17.77M$15.73M$14.31M$13.88M$14.95M$15.68M$16.13M
Selling, general and administrative$19.87M$19.54M$18.9M$19.03M$19.28M$20.98M$21.22M$21.23M
Research and development$4.7M$5.08M$5.63M$5.69M$3.75M$5.12M$6.28M$4.85M
Total operating expenses$24.57M$24.62M$24.53M$24.72M$23.03M$26.1M$27.51M$26.08M
Operating income-$2.63M-$6.86M-$8.8M-$10.41M-$9.15M-$11.15M-$11.83M-$9.96M
Interest expense-$1.48M-$1.46M-$1.42M-$1.25M-$1.27M-$1.25M-$1.23M-$1.3M
Income before taxes-$6.16M-$7.63M-$10.62M-$11.64M-$13.17M-$9.92M-$13.85M-$11.57M
Income taxes$65K$33K-$11K-$17K$15K$4K$8K$19K
Net income-$6.22M-$7.66M-$10.61M-$11.62M-$13.19M-$9.92M-$13.86M-$11.59M
Net income attributable to common shareholders-$6.22M-$7.66M-$10.61M-$11.62M-$13.19M-$9.92M-$13.86M-$11.59M
EBITDA-$2.04M-$6.25M-$8.18M-$9.71M-$8.58M-$10.6M-$11.31M-$9.55M
Basic earnings per share-$0.20-$0.25-$0.35-$0.38-$0.46-$0.38-$0.53-$0.44
Diluted earnings per share-$0.20-$0.25-$0.35-$0.38-$0.46-$0.38-$0.53-$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

Avita Medical Inc. (RCEL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by institutional investor buying pressure.

GlobeNewswire Inc.

AVITA Medical to Host Investor Webinar Briefing

AVITA Medical announced strong third quarter 2026 results with 53% year-over-year revenue growth and raised its full year 2026 revenue guidance. The company also announced that the Centers for Medicare & Medicaid Services finalized national physician payment values and simplified billing codes for RECELL procedures effective 2027. An investor webinar is scheduled for November 11, 2026.

GlobeNewswire Inc.

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

AVITA Medical announced its participation at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11-13, 2026. CEO Cary Vance will speak on August 12 at 8:00 a.m. ET, with a live webcast available on the company's investor relations website.

GlobeNewswire Inc.

Scar Treatment Market Size is Expected to Reach USD 56.30 Billion by 2033; Growth is Propelling Due to the Surging Awareness for Advanced Cosmetic and Reconstructive Procedures Globally

The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.

GlobeNewswire Inc.

Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

AVITA Medical presented 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of its three technologies (RECELL, PermeaDerm, and Cohealyx) in patient cases. New clinical and histological data demonstrated that RECELL use was associated with smaller donor sites, faster healing times, improved pain and appearance outcomes, and more favorable health economics. Real-world studies showed RECELL reduced hospital stays by up to 36% in deep partial-thickness burns and nearly 16 days shorter stays in elderly burn patients.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.